Renalytix (LON:RENX) Trading Down 1.7% – What’s Next?

Shares of Renalytix Plc (LON:RENX) fell 1.7% on Monday . The stock traded as low as GBX 5.80 and last traded at GBX 5.80. 561,166 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 1,471,433 shares. The stock had previously closed at GBX 5.90.

Renalytix Trading Down 1.7%

The company has a debt-to-equity ratio of -72.91, a current ratio of 0.24 and a quick ratio of 2.42. The firm has a market cap of £25.35 million, a price-to-earnings ratio of -0.83 and a beta of 2.10. The business’s 50-day moving average price is GBX 6.94 and its two-hundred day moving average price is GBX 7.21.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).